Retinoid X receptor (RXR) is a nuclear receptor that heterodimerizes with a number of nuclear receptors, integrating ligand-mediated alerts throughout the heterodimers. Artificial RXR agonists have been developed to treatment sure inflammatory ailments, together with inflammatory bowel ailments (IBDs). Nonetheless, pre-existing RXR agonists, that are lipophilic and readily absorbed within the higher gut, trigger appreciable hostile results corresponding to hepatomegaly, hyperlipidemia, and hypothyroidism.
To attenuate these hostile results, now we have developed an RXR agonist, NEt-3IB, which has lipophilic and thus poorly absorptive properties. On this research, we evaluated the consequences of NEt-3IB in an experimental murine colitis mannequin induced via the adoptive switch of CD45RBexcessiveCD4+ T cells.
Pharmacokinetic research demonstrated that the key portion of NEt-3IB was efficiently delivered to the massive gut after oral administration. Notably, NEt-3IB remedy suppressed the event of T cell-mediated power colitis, as indicated by enchancment of losing signs, inflammatory infiltration, and mucosal hyperplasia. The protecting impact of NEt-3IB was mediated by the suppression of IFN-γ-producing Th1 cell enlargement within the colon. In conclusion, NEt-3IB, a big intestine-directed RXR agonist, is a promising drug candidate for IBDs.
Acute Kidney Damage Following Chimeric Antigen Receptor T–Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient
Anti-CD19 chimeric antigen receptor (CAR) T-cell remedy is a more recent and efficient therapeutic possibility authorised for sufferers with relapsed/refractory acute lymphoblastic leukemia and diffuse giant B-cell lymphoma. Acute kidney damage is a complication of CAR T-cell remedy that may end up in kidney failure. Most often, it’s regarded as associated to hemodynamic modifications as a consequence of cytokine launch syndrome. Kidney biopsy on this scientific state of affairs is often not carried out.
We report on a kidney transplant recipient in his 40s who developed a posttransplant lymphoproliferative dysfunction of B-cell origin refractory to traditional therapies and obtained anti-CD19 CAR T-cell remedy as compassionate remedy. Starting on day 12 after CAR T-cell infusion, within the absence of scientific signs, a progressive decline in estimated glomerular filtration price of the kidney graft occurred.
A subsequent allograft biopsy confirmed delicate tubulointerstitial lymphocyte infiltrates, falling right into a Banff borderline-changes class and resembling an acute immunoallergic tubulointerstitial nephritis. Neither CAR T cells nor lymphomatous B cells had been detected throughout the graft mobile infiltrates, suggesting an oblique mechanism of kidney damage. Though kidney graft perform partially recovered after steroid remedy, the posttransplant lymphoproliferative dysfunction progressed and the affected person died 7 months later.
Expression and scientific significance of inhibitory receptor Leukocyte-associated immunoglobulin-like receptor-1 on peripheral blood T cells of power hepatitis B sufferers: A cross-sectional research
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an inhibitory receptor that’s expressed on the floor of a number of immune cells and performs key roles in immune modulation. In sufferers with power hepatitis B (CHB), T cell quantity and features are irregular and the expression of inhibitory receptors is elevated. Nonetheless, the expression of LAIR-1 on T cells in sufferers with CHB remains to be undetermined.We recruited 320 sufferers with CHB in several illness phases and 17 wholesome donors.
Serum biochemical and virological examinations had been carried out for every participant, and their demographic and scientific information had been collected. In keeping with the most recent American Affiliation for the Research of Liver Illness pointers, we categorized the sufferers into four teams: immune energetic, immune tolerant, inactive CHB, and grey zone. Moreover, we examined the expression of LAIR-1 on T cells and T cell subsets utilizing move cytometry.
We noticed a big lower in LAIR-1 expression on CD3+ T cells and its two subsets (CD4+ and CD8+ T cells) in sufferers with CHB. LAIR-1 expression on T cells was the bottom within the immune energetic group. LAIR-1 expression ranges on CD4+ and CD8+ T cells confirmed a big damaging affiliation with hepatitis B virus (HBV) DNA load and had been decrease in hepatitis B e antigen (HBeAg)-positive sufferers than in HBeAg-negative sufferers (P < .05).
As well as, LAIR-1 expression ranges on CD3+, CD4+, and CD8+ T cells had been all negatively related to liver irritation and fibrosis parameters, corresponding to alanine aminotransferase and aspartate aminotransferase ranges, FibroScan worth, and aspartate aminotransferase-to-platelet ratio index rating.LAIR-1 expression ranges on T cells had been related to HBV DNA load and liver irritation and fibrosis parameters, indicating that LAIR-1 might play an essential regulatory function in HBV-induced T cell immune pathogenesis and could also be a therapeutic goal for CHB.
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in power lymphocytic leukemia
Chimeric antigen receptor (CAR) T cells have induced outstanding antitumor responses in B cell malignancies. Some sufferers don’t reply due to T cell deficiencies that hamper the enlargement, persistence, and effector perform of those cells. We used longitudinal immune profiling to establish phenotypic and pharmacodynamic modifications in CD19-directed CAR T cells in sufferers with power lymphocytic leukemia (CLL). CAR expression upkeep was additionally investigated as a result of this could have an effect on response sturdiness.
CAR T cell failure was accompanied by preexisting T cell-intrinsic defects or dysfunction acquired after infusion. In a small subset of sufferers, CAR silencing was noticed coincident with leukemia relapse. Utilizing a small molecule inhibitor, we demonstrated that the bromodomain and extra-terminal (BET) household of chromatin adapters performs a task in downregulating CAR expression.
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx139531-01mg | Abbexa | 0.1 mg | EUR 427.2 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx139532-01mg | Abbexa | 0.1 mg | EUR 427.2 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx021457-02mg | Abbexa | 0.2 mg | EUR 560.4 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| 20-abx009132 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx412166-01mg | Abbexa | 0.1 mg | EUR 844.8 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx413013-05mg | Abbexa | 0.5 mg | EUR 861.6 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx413228-02mg | Abbexa | 0.2 mg | EUR 678 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx413229-05mg | Abbexa | 0.5 mg | EUR 994.8 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx413232-01mg | Abbexa | 0.1 mg | EUR 526.8 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx413235-20ug | Abbexa | 20 ug | EUR 326.4 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx415026-02mg | Abbexa | 0.2 mg | EUR 678 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx415028-25ug | Abbexa | 25 ug | EUR 326.4 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx415520-02mg | Abbexa | 0.2 mg | EUR 678 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx415521-05mg | Abbexa | 0.5 mg | EUR 994.8 |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
|||
| abx415524-01mg | Abbexa | 0.1 mg | EUR 526.8 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx113198 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx103611 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx103612 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx103613 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx103614 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx104897 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx130249 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx130845 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx131791 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx125344 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx018080-100ug | Abbexa | 100 ug | EUR 460.8 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx004278 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx010962-100ul | Abbexa | 100 ul | EUR 493.2 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx000682 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx210388 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx210389 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx211168 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx211280 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (Icam1) Antibody |
|||
| abx234099-100ug | Abbexa | 100 ug | EUR 661.2 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx270132 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx270160 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx270161 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx172974 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx172975 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx172976 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx172977 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx330433-100ul | Abbexa | 100 ul | EUR 510 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx302191 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159548-100ul | Abbexa | 100 ul | EUR 560.4 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159549-100ul | Abbexa | 100 ul | EUR 560.4 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx432833-200ul | Abbexa | 200 ul | EUR 460.8 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx432834-200ul | Abbexa | 200 ul | EUR 460.8 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| 20-abx323264 | Abbexa |
|
|
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx113198-100l | Abbexa | 100 µl | EUR 612.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159548-100g | Abbexa | 100 µg | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159548-10g | Abbexa | 10 µg | EUR 437.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159548-50g | Abbexa | 50 µg | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159549-100g | Abbexa | 100 µg | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159549-10g | Abbexa | 10 µg | EUR 437.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx159549-50g | Abbexa | 50 µg | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx210388-100l | Abbexa | 100 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx210388-50l | Abbexa | 50 µl | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx210389-100l | Abbexa | 100 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx210389-50l | Abbexa | 50 µl | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx130249-100l | Abbexa | 100 µl | EUR 212.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx130249-1ml | Abbexa | 1 ml | EUR 475 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx130249-200l | Abbexa | 200 µl | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172974-100l | Abbexa | 100 µl | EUR 775 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172974-1ml | Abbexa | 1 ml | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172974-200l | Abbexa | 200 µl | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172975-100l | Abbexa | 100 µl | EUR 275 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172975-1ml | Abbexa | 1 ml | EUR 775 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172975-200l | Abbexa | 200 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172976-100l | Abbexa | 100 µl | EUR 812.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172976-1ml | Abbexa | 1 ml | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172976-200l | Abbexa | 200 µl | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172977-100l | Abbexa | 100 µl | EUR 850 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172977-1ml | Abbexa | 1 ml | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx172977-200l | Abbexa | 200 µl | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx211168-100l | Abbexa | 100 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx211168-50l | Abbexa | 50 µl | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx211280-100l | Abbexa | 100 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx211280-50l | Abbexa | 50 µl | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx177024-1096tests | Abbexa | 10 × 96 tests | EUR 725 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx177024-596tests | Abbexa | 5 × 96 tests | EUR 337.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx177024-96tests | Abbexa | 96 tests | EUR 262.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx302191-100g | Abbexa | 100 µg | EUR 362.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx302191-20g | Abbexa | 20 µg | EUR 162.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx302191-50g | Abbexa | 50 µg | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx018080-1mg | Abbexa | 1 mg | EUR 300 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx270132-1ml | Abbexa | 1 ml | EUR 425 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx270132-200l | Abbexa | 200 µl | EUR 300 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx270160-1ml | Abbexa | 1 ml | EUR 425 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx270160-200l | Abbexa | 200 µl | EUR 300 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx270161-1ml | Abbexa | 1 ml | EUR 425 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx270161-200l | Abbexa | 200 µl | EUR 300 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx131791-100g | Abbexa | 100 µg | EUR 625 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx131791-20g | Abbexa | 20 µg | EUR 300 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx131791-5g | Abbexa | 5 µg | EUR 237.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx130845-100l | Abbexa | 100 µl | EUR 287.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx130845-500l | Abbexa | 500 µl | EUR 362.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx139530-100l | Abbexa | 100 µl | EUR 275 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx139530-500l | Abbexa | 500 µl | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx139531-100l | Abbexa | 100 µl | EUR 275 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx139531-500l | Abbexa | 500 µl | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx139532-100l | Abbexa | 100 µl | EUR 275 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx139532-500l | Abbexa | 500 µl | Ask for price |
Intercellular Adhesion Molecule 1 (Icam1) Antibody |
|||
| abx234099-100g | Abbexa | 100 µg | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx413229-200l | Abbexa | 200 µl | EUR 737.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx413235-200l | Abbexa | 200 µl | EUR 175 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx415026-200l | Abbexa | 200 µl | EUR 562.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx415028-200l | Abbexa | 200 µl | EUR 337.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx415520-200l | Abbexa | 200 µl | EUR 487.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx415521-200l | Abbexa | 200 µl | EUR 775 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx415524-200l | Abbexa | 200 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx402044-100tests | Abbexa | 100 tests | EUR 287.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx432833-100g | Abbexa | 100 µg | EUR 387.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx432834-100g | Abbexa | 100 µg | EUR 387.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx341084-100l | Abbexa | 100 µl | EUR 350 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx341084-50l | Abbexa | 50 µl | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx323264-100g | Abbexa | 100 µg | EUR 250 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx323264-50g | Abbexa | 50 µg | EUR 187.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx004278-100l | Abbexa | 100 µl | EUR 400 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx004278-20l | Abbexa | 20 µl | EUR 175 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx004278-50l | Abbexa | 50 µl | EUR 275 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx010962-100g | Abbexa | 100 µg | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx010962-10g | Abbexa | 10 µg | EUR 362.5 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx010962-200g | Abbexa | 200 µg | Ask for price |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx104897-100g | Abbexa | 100 µg | EUR 775 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx104897-20g | Abbexa | 20 µg | EUR 275 |
Intercellular Adhesion Molecule 1 (ICAM1) Antibody |
|||
| abx104897-50g | Abbexa | 50 µg | EUR 350 |
BET protein blockade additionally ameliorated CAR T cell exhaustion as manifested by inhibitory receptor discount, enhanced metabolic health, elevated proliferative capability, and enriched transcriptomic signatures of T cell reinvigoration. BET inhibition decreased ranges of the TET2 methylcytosine dioxygenase, and compelled expression of the TET2 catalytic area eradicated the potency-enhancing results of BET protein focusing on in CAR T cells, offering a mechanism linking BET proteins and T cell dysfunction. Thus, modulating BET epigenetic readers might enhance the efficacy of cell-based immunotherapies.
